Received Nov 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | IM / LA |
redness, swelling and muscle soreness to last at the Shingrix injection site; swelling and muscle soreness to last at the Shingrix injection site; muscle soreness to last at the Shingrix injection site; warmth at the injection site (injection site is hot); This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date). On 27-OCT-2025, the patient received the 2nd dose of Shingrix (intramuscular, left deltoid). In OCT-2025, an unknown time after receiving Shingrix, the patient experienced injection site erythema (Verbatim: redness, swelling and muscle soreness to last at the Shingrix injection site), injection site swelling (Verbatim: swelling and muscle soreness to last at the Shingrix injection site), injection site pain (Verbatim: muscle soreness to last at the Shingrix injection site) and injection site warmth (Verbatim: warmth at the injection site (injection site is hot)). The outcome of the injection site erythema was resolving and the outcome of the injection site swelling and injection site warmth were not resolved and the outcome of the injection site pain was unknown. It was unknown if the reporter considered the injection site erythema, injection site swelling, injection site pain and injection site warmth to be related to Shingrix. It was unknown if the company considered the injection site erythema, injection site swelling, injection site pain and injection site warmth to be related to Shingrix. Additional Information: GSK Receipt Date: 30-OCT-2025 The reporter was the patient. The patient said that how long could she expect the redness, swelling and muscle soreness to last at the Shingrix injection site. She did not have the lot number. She did not thought the pharmacy gave it to her and she was not at her home during this call to check the paperwork. She also mentioned that the injection site is hot not terribly bad but if put hand over it and slide down closer to the elbow it was definitely cooler than the spot up above. The reporter thought the redness was a little less than before day of reporting, but it was still pretty swollen. The batch number was not provided and a request for this information has been made.